Vanguard's Model Evolves
Executive SummaryVanguard's founders believed they could pick preclinical compounds destined to become successful drugs and develop them cost-effectively with a virtual organization using CROs. To get access to other companies' compounds, Vanguard agrees to fund development--and to give the originator the option to reacquire the drug for marketing. But the original model's weaknesses--high risk, high cost, and perhaps not so high a return--have become apparent. Vanguard's trying to adjust the model appropriately.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.